Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues in delivering DCs for immunotherapy.

S M Barratt-Boyes1, C G Figdor

  • 1Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pennsylvania, Pittsburgh, USA.

Cytotherapy
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Elimination of Autoreactive B Cells Using Multivalent Polyisocyanopeptide-Based Antigen-Toxin Conjugates.

Biomacromolecules·2026
Same author

The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture.

Nature communications·2020
Same author

Cross-talk between iNKT cells and CD8 T cells in the spleen requires the IL-4/CCL17 axis for the generation of short-lived effector cells.

Proceedings of the National Academy of Sciences of the United States of America·2019
Same author

Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018
Same author

Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo.

Gene therapy·2017
Same author

Dual-color superresolution microscopy reveals nanoscale organization of mechanosensory podosomes.

Molecular biology of the cell·2013
Same journal

CAR T cells: The next frontier.

Cytotherapy·2026
Same journal

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Cytotherapy·2026
Same journal

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Cytotherapy·2026
Same journal

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026
Same journal

Manufacturing strategies for prolonged CAR-T cell persistence.

Cytotherapy·2026
Same journal

Overcoming five main challenges to targeting hematologic malignancies.

Cytotherapy·2026
See all related articles

Dendritic cell (DC)-based immunotherapy shows promise for cancer treatment. Further controlled clinical trials are essential to optimize DC delivery methods, including injection route, frequency, and cell number, for maximum therapeutic success.

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Dendritic cell (DC)-based immunotherapy is a promising strategy in clinical cancer trials.
  • Mature DCs are crucial for initiating tumor-specific immune responses.

Purpose of the Study:

  • To address the ongoing debate regarding the optimal delivery methods for DC-based cancer immunotherapy.
  • To identify the most effective routes, frequencies, and cell numbers for DC injections in clinical settings.

Main Methods:

  • The study emphasizes the need for controlled clinical trials to investigate DC delivery parameters.
  • No specific experimental methods are detailed in the abstract; the focus is on the need for future research.

Main Results:

Related Experiment Videos

  • The abstract does not present specific results but highlights areas of uncertainty.
  • Key questions remain regarding the optimal route, frequency, and cell dosage for DC immunotherapy.

    • Conclusions:

    • Controlled clinical trials are necessary to determine optimal DC delivery strategies for cancer immunotherapy.
    • Establishing standardized protocols for DC administration is critical for improving patient outcomes.